After the panel vote, Commissioner Stephen Hahn said the FDA plans to “act quickly”.
2 min read
This article has been translated from our English edition.
This story originally appeared on Business Insider
A panel of independent experts will meet today to discuss the Coronavirus vaccination Pfizer. At the end of the day, they are expected to come to a vote that will advise the U.S. Food and Drug Administration (FDA) to approve or deny the emergency injection.
But the commissioner of the FDADr. Stephen Hahn said the outcome was already predictable and the agency intends to act immediately on advice from the advisory body.
“We’ll have to see what the scientific and medical discussion is like today. However, our plan is to consider your recommendations for our decision-making and make a decision shortly thereafter … We intend to act quickly,” he told Savannah Guthrie to NBC News before the advisory board met.
The FDA chief said, “Our first assessment is that this is a vaccine that meets our criteria … but we want to hear from the Vaccine Advisory Committee.”
If approved, high priority Americans, including nursing home residents and healthcare workers, are expected to receive the vaccine in the coming days.
Pfizer’s vaccine has been shown to be safe and 95% effective in preventing symptomatic COVID-19. However, the advisory panel is likely to discuss the pros and cons of approving a vaccine that still has many unknowns, such as: B. whether it protects against asymptomatic infections and “silent spread”, how long its protection against COVID-19 lasts and whether enough data is available. on older Americans to justify injecting some of them first.